Breast cancer survivor offers wisdom at Faulkner satellite center
Call 877-422-3324 today to make an appointment
Make your appointment or second opinion with Dana-Farber today to meet with an onsite specialist.
Can’t get to Boston? Explore our Online Second Opinion service to get expert advice from Dana-Farber oncologists.
Toll-Free Number866-408-DFCI (3324)
Discover the ways to give and how to get involved to support Dana-Farber.
Poet Richard Fox gains insight – and material – through cancer treatment
A family faces cancer in an unfamiliar city – with help
Choosing mastectomy or not: Studying young women's surgical choices
Jeff's targeted therapy has kept his advanced lung cancer at bay.
With 180,000 men diagnosed with prostate cancer each year, it is one
of the most common types of cancer in the country. For this reason, it
has been cited as a good marker for health care spending in general,
reflective of the greater trends across the United States.
New research from the Dana-Farber/Brigham and Women's Cancer Center
(DF/BWCC) shows that newer, more expensive treatment options for
prostate cancer were adopted rapidly and widely during 2002–2005 without
proof of their cost-effectiveness, and may offer explanations for why
health care spending accounts for 17 percent of the nation's GDP. This
research is published online and will appear in the March 14 print
edition of the Journal of Clinical Oncology.
"In an era of limited resources, it is important for us as a society to take stock of how we're spending our money", said Paul Nguyen, MD, lead author of the study and a radiation oncologist at the Dana-Farber/Brigham and Women's Cancer Center.
"We don't think these patterns are unique to prostate cancer," he
said, "but used it as an example and found that in the United States,
newer and more expensive technologies were rapidly adopted before we
knew if they were worth the added cost — or, in the case of robotic
surgery, whether they provide benefits over standard treatment."
Researchers evaluated the use and cost of surgical and radiation
treatments for prostate cancer using Medicare-linked data from more than
45,000 men who were 65 years or older between 2002 and 2005.
The data accounted for patients who received two types of surgical
treatments: the older treatment, open radical prostatectomy, and the
newer treatment, robot-assisted or laparoscopic prostatectomy; and two
types of radiation treatments: the older type, three-dimensional
conformal radiation therapy (3D-CRT), and the newer option,
intensity-modulated radiation therapy (IMRT).
Researchers report that among surgical patients, the number who
received robot-assisted or laparoscopic prostatectomy increased
substantially from 1.5 percent of diagnoses in 2002 to 28.7 percent of
diagnoses in 2005.
Among patients who received radiation therapy, researchers observed
the same trend towards rapid adoption of IMRT, the newer treatment
option. In 2002, 28.7 percent of men diagnosed received IMRT compared to
81.7 percent in 2005. Additionally, among men who received
brachytherapy, supplemental IMRT increased from 8.5 percent in 2002 to
31.1 percent in 2005. Patients receiving the newer type of therapy
tended to live in higher-income and metropolitan regions, and were more
likely to have earlier stage disease and be of Asian descent.
Researchers also report that Medicare spending on the newer treatment
options was significantly higher than on traditional treatments, with
the difference between IMRT and 3D-CRT being nearly $11,000 per patient,
and the difference between robot-assisted prostatectomy and open
radical prostatectomy being $293, although the authors suggest that this
is an underestimate of the underlying cost differences in the
surgeries, since it does not account for the cost of purchasing and
maintaining the robot.
After extrapolating these numbers to the total U.S. population,
researchers report an additional of spending adding up to nearly $350
million in 2005 on newer treatment options when compared to the
traditional and less costly alternative therapy for men diagnosed with
"Our paper should not be interpreted as being 'anti-technology,' and
we do not want to stand in the way of bringing newer and better
treatments to market," Nguyen said. "On the other hand, health care
spending is a zero-sum game, and a greater emphasis on comparative
effectiveness research is needed so we can better separate the wheat
from the chaff. While IMRT has proven itself to significantly reduce the
rate of serious rectal bleeding after prostate radiation, the study to
show it is cost-effective was not published until 2006, when over 80% of
the country was already using it. In the case of robotic surgery, there
are still uncertainties over what benefits it has over the open
This research was funded through grants from the Department of Defense and the JCRT Foundation.